Previous close | 2.8200 |
Open | 2.9000 |
Bid | 3.4000 x 100 |
Ask | 0.0000 x 0 |
Day's range | 2.6700 - 4.3300 |
52-week range | 2.2300 - 18.7000 |
Volume | |
Avg. volume | 43,934 |
Market cap | 2.028M |
Beta (5Y monthly) | 2.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | -16.0000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 700.00 |
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has received a non-binding Letter of Intent ("LoI") from the European Investment Bank (the "EIB"). This LoI outlines specific indicative terms for converting the EIB's loan into equity in the form of prefunded warrants, which are exerci
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that on June 5, 2024, it received formal notification from the Listing Qualification Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") that the Company has regained compliance with the minimum $1.00 bid price requirement set forth
Scinai Immunotherapeutics Ltd. (the "Company") (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced the receipt of an additional Nasdaq Staff determination letter regarding noncompliance with the minimum shareholders' equity required for continued listing and a hearing with the Nasdaq Hearings Panel (the "Hearings Panel") to present a pla